Kemistar [KEMISTAR] vs Kingfa Science [KINGFA] Detailed Stock Comparison
Kemistar
BSE
Loading...
Kingfa Science
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Kemistar wins in 3 metrics, Kingfa Science wins in 16 metrics, with 0 ties. Kingfa Science appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kemistar | Kingfa Science | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 113.82 | 30.12 | Kingfa Science |
| Price-to-Book Ratio | 3.72 | 6.35 | Kemistar |
| Debt-to-Equity Ratio | 43.92 | 5.90 | Kingfa Science |
| PEG Ratio | N/A | 16.19 | N/A |
| EV/EBITDA | 159.04 | 20.76 | Kingfa Science |
| Profit Margin (TTM) | 3.34% | 8.58% | Kingfa Science |
| Operating Margin (TTM) | 6.77% | 11.17% | Kingfa Science |
| EBITDA Margin (TTM) | 6.77% | 11.17% | Kingfa Science |
| Return on Equity | 3.26% | 20.98% | Kingfa Science |
| Return on Assets (TTM) | 2.08% | 13.23% | Kingfa Science |
| Free Cash Flow (TTM) | $-21.00M | $295.94M | Kingfa Science |
| Dividend Yield | 0.67% | 0.32% | Kemistar |
| 1-Year Return | -17.22% | 31.52% | Kingfa Science |
| Price-to-Sales Ratio (TTM) | 3.95 | 2.58 | Kingfa Science |
| Enterprise Value | $785.09M | $46.42B | Kingfa Science |
| EV/Revenue Ratio | 4.52 | 2.59 | Kingfa Science |
| Gross Profit Margin (TTM) | 14.47% | 22.30% | Kingfa Science |
| Revenue per Share (TTM) | $16 | $1,478 | Kingfa Science |
| Earnings per Share (Diluted) | $0.56 | $126.75 | Kingfa Science |
| Beta (Stock Volatility) | -0.17 | 0.66 | Kemistar |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Kemistar vs Kingfa Science Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kemistar | 3.77% | 0.46% | -8.79% | -18.04% | -18.87% | -31.73% |
| Kingfa Science | 8.58% | 9.13% | 12.07% | 18.51% | 37.66% | 11.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kemistar | -17.22% | 58.36% | 51.76% | 98.44% | -88.07% | -88.07% |
| Kingfa Science | 31.52% | 278.86% | 672.29% | 1,316.36% | 10,861.24% | 12,694.24% |
Performance & Financial Health Analysis: Kemistar vs Kingfa Science
| Metric | KEMISTAR | KINGFA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹685.80M | ₹46.24B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 6,487 | 17,014 |
| 90 Day Avg. Volume | 4,184 | 14,157 |
| Last Close | ₹66.14 | ₹4,145.30 |
| 52 Week Range | ₹55.80 - ₹116.45 | ₹2,550.00 - ₹4,190.00 |
| % from 52W High | -43.20% | -1.07% |
| All-Time High | ₹562.50 (Aug 29, 2011) | ₹4,190.00 (Aug 18, 2025) |
| % from All-Time High | -88.24% | -1.07% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.21% | 0.11% |
| Quarterly Earnings Growth | -0.16% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.09% |
| Operating Margin (TTM) | 0.07% | 0.11% |
| Return on Equity (TTM) | 0.03% | 0.21% |
| Debt to Equity (MRQ) | 43.92 | 5.90 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹17.13 | ₹601.64 |
| Cash per Share (MRQ) | ₹0.65 | ₹19.54 |
| Operating Cash Flow (TTM) | ₹11.70M | ₹993.76M |
| Levered Free Cash Flow (TTM) | ₹6.01M | ₹1.53B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.67% | 0.32% |
| Last 12-Month Dividend | ₹0.50 | ₹10.00 |
Valuation & Enterprise Metrics Analysis: Kemistar vs Kingfa Science
| Metric | KEMISTAR | KINGFA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 113.82 | 30.12 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | 16.19 |
| Price to Sales (TTM) | 3.95 | 2.58 |
| Price to Book (MRQ) | 3.72 | 6.35 |
| Market Capitalization | ||
| Market Capitalization | ₹685.80M | ₹46.24B |
| Enterprise Value | ₹785.09M | ₹46.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.52 | 2.59 |
| Enterprise to EBITDA | 159.04 | 20.76 |
| Risk & Other Metrics | ||
| Beta | -0.17 | 0.66 |
| Book Value per Share (MRQ) | ₹17.13 | ₹601.64 |
Financial Statements Comparison: Kemistar vs Kingfa Science
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KEMISTAR | KINGFA |
|---|---|---|
| Revenue/Sales | ₹70.27M | ₹4.70B |
| Cost of Goods Sold | ₹60.10M | ₹3.63B |
| Gross Profit | ₹10.17M | ₹1.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.86M | ₹905.70M |
| EBITDA | ₹5.34M | ₹623.82M |
| Pre-Tax Income | ₹3.97M | ₹543.29M |
| Income Tax | ₹1.12M | ₹124.31M |
| Net Income (Profit) | ₹2.85M | ₹418.98M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KEMISTAR | KINGFA |
|---|---|---|
| Cash & Equivalents | ₹2.70M | ₹234.80M |
| Total Current Assets | ₹59.97M | ₹8.54B |
| Total Current Liabilities | ₹40.93M | ₹4.22B |
| Long-Term Debt | ₹64.35M | ₹20.61M |
| Total Shareholders Equity | ₹184.36M | ₹7.29B |
| Retained Earnings | N/A | ₹4.55B |
| Property, Plant & Equipment | ₹142.10M | ₹2.44B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KEMISTAR | KINGFA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KEMISTAR | KINGFA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,487 | 17,014 |
| Average Daily Volume (90 Day) | 4,184 | 14,157 |
| Shares Outstanding | 10.76M | 12.11M |
| Float Shares | 2.36M | 1.66M |
| % Held by Insiders | 0.79% | 0.86% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Kemistar vs Kingfa Science
| Metric | KEMISTAR | KINGFA |
|---|---|---|
| Last 12-Month Dividend | ₹0.50 | ₹10.00 |
| Last 12-Month Dividend Yield | 0.67% | 0.32% |
| 3-Year Avg Annual Dividend | ₹0.43 | ₹3.33 |
| 3-Year Avg Dividend Yield | 0.83% | 0.30% |
| 3-Year Total Dividends | ₹1.30 | ₹10.00 |
| Ex-Dividend Date | Sep 23, 2024 | Sep 17, 2024 |